Login to Your Account

Bavarian Nordic Rises on First Vaccine Approval

By Cormac Sheridan
Staff Writer

Wednesday, August 14, 2013

Shares in Bavarian Nordic A/S gained 6.6 percent on news that the European Commission had formally approved its third-generation smallpox vaccine Imvanex, based on a modified vaccinia Ankara (MVA) vector.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription